Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery.

Created on 11 Aug 2026

Authors

Sergi Marco, Peter J Walsh, Alexey S Revenko, Tobias Schmidt, Peter A Thomason, Lynn McGarry, A Robert MacLeod, Sonam Ansel, Dina Tataran, Martin Bushell, Chiara Braconi, Jim C Norman

Published in

The Journal of cell biology. Volume 225. Issue 9. Sep 07, 2026. Epub Aug 11, 2026.

Abstract

The potential for using therapeutic antisense oligonucleotides (ASOs) has been hampered by a lack of understanding of how they enter cells and subsequently access their targets. Endocytosis contributes to ASO uptake, but the machinery mediating subsequent ASO trafficking to permit suppression of their target mRNAs has not been described. Here, we show that direct ASO engagement with a scavenger receptor (CD44) activates the ERK-RSK axis to promote serine phosphorylation of a receptor tyrosine kinase (EPHA2). Serine phosphorylation of EPHA2 permits endocytosis, trafficking, and accumulation of ASOs in nuclear-captured endosomes. These endosomes are then subject to lipid peroxidation and become leaky, allowing ASOs to escape and effectively suppress target mRNA expression. Inhibition of stress granule-mediated repair of these leaky endosomes further enhances ASO effectiveness. These data identify an endocytic route to the nucleus which may be exploited to maximize the effectiveness of ASO-mediated therapies.

PMID:
42578958
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement